bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)
Authors: Stacchiotti Silvia , Pantaleo Maria A. , Negri Tiziana , Astolfi Annalisa , Tazzari Marcella , Dagrada Gian Paolo , Urbini Milena , Indio Valentina , Maestro Roberta , Gronchi Alessandro , Fiore Marco , Dei Tos Angelo P. , Conca Elena , Palassini Elena , Vincenzi Bruno , Grosso Federica , Pilotti Silvana , Castelli Chiara , Casali Paolo G.
Published: April 2023

Supplementary Figure 1. Evidence of tumor regression and inflammatory infiltration in IM-treated metastatic FS-DFSP. IHC staining of a metastatic FS-DFSP lesions derived from patient #4 in Table 1 and 2. Panel A and B show haematoxylin and eosin stains of (a, b) pre-IM and (c, d, e, f) post-IM lesions. Micrograph picture c shows the presence of a cellular depleted area replaced by hyalinized stroma. Panel B displays the intra-tumor presence of inflammatory cells (indicated by the arrows). Original magnification: a and c 25x; d and e 50x; b and f 100x.
Supplementary Figs from MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Authors: Hew Karina E. , Miller Philip C. , El-Ashry Dorraya , Sun Jun , Besser Alexandra H. , Ince Tan A. , Gu Mengnan , Wei Zhi , Zhang Gao , Brafford Patricia , Gao Wei , Lu Yiling , Mills Gordon B. , Slingerland Joyce M. , Simpkins Fiona
Published: April 2023

Supplementary Figure 1. (A) Percent of HGSOCs from the TCGA cohort with mutations in 42 genes associated with the RAS/Raf/MEK/MAPK pathway (N=45/311); (B) Percent of HGSOCs from the TCGA cohort with copy number amplifications or mRNA overexpression of 42 MAPK pathway genes (N=232/311) Supplementary Figure 2. (A); Percent of high-pMAPK and low-pMAPK HGSOCs as defined by RPPA from the TCGA cohort with (A) copy number amplification (B) mRNA overexpression, (C) mutation in which MAPK pathway genes are genetically activated in hMAPK cancers. The numbers with data available for each analysis in TCGA are shown below graphs. Supplementary Figure 3. Dose dependent effects of selumetinib on ER positive, MAPK kinase activated ovarian cancer cells Supplementary Figure 4. In vitro cell cycle effects of MEK and ER inhibition on ER+ BG-1 OVCA cells Supplementary Figure 5: Gene expression changes expressed as log fold change over baseline control untreated cell values after 48 hours of treatment with fulvestrant (1 μM), selumetinib (200 nM) or both, in vitro of representative genes in (A) ER target gene expression (B) Cell signaling pathways (C) Cell cycle pathways. Supplementary Figure 6. Heat map representation of selected triplicate repeat RPPA data from PEO1-R cells treated with either monotherapy fulvestrant (FULV), selumetinib (MEK I) or dual therapy as indicated. Heat map demonstrates inter-sample variability in triplicate repeat assays. Supplementary Table 1. List of genes in the 126 gene MAPK activation profile common to the TCGA and JAPAN cohorts. Supplementary Table 2. Differences in gene mutation, overexpression and amplification between low and high pMAPK HGSOC as defined by RPPA in TCGA cohort Supplementary Table 3.Analysis of xenograft growth rates reveal synergy between fulvestrant and selumetinib therapy on OVCA PEOIR xenograft growth
Supplemental Table 2 from SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Authors: Della Corte Carminia Maria , Bellevicine Claudio , Vicidomini Giovanni , Vitagliano Donata , Malapelle Umberto , Accardo Marina , Fabozzi Alessio , Fiorelli Alfonso , Fasano Morena , Papaccio Federica , Martinelli Erika , Troiani Teresa , Troncone Giancarlo , Santini Mario , Bianco Roberto , Ciardiello Fortunato , Morgillo Floriana
Published: April 2023

Intensity score , percentage score and IHC score of Vimentina, MET and PTCH on tumor xenografts in nude mice collected at the end of treatment.
Supplementary Figure 1 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Authors: Daver Naval , Boumber Yanis , Kantarjian Hagop , Ravandi Farhad , Cortes Jorge , Rytting Michael E. , Kawedia Jitesh D. , Basnett Jordan , Culotta Kirk S. , Zeng Zhihong , Lu Hongbo , Richie Mary Ann , Garris Rebecca , Xiao Lianchun , Liu Wenbin , Baggerly Keith A. , Jabbour Elias , O'Brien Susan , Burger Jan , Bendall Linda J. , Thomas Deborah , Konopleva Marina
Published: April 2023

Supplementary Figure 1.Baseline 4EBP1 and outcomes.
Supplemental Figure Legends and Mathods from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure Legends and Mathods. Description of supplemental figure contents and methods used in the related studies.
Supplemental Figure 4 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
Authors: Yamamoto Yoshiaki , Loriot Yohann , Beraldi Eliana , Zhang Fan , Wyatt Alexander W. , Nakouzi Nader Al , Mo Fan , Zhou Tianyuan , Kim Youngsoo , Monia Brett P. , MacLeod A. Robert , Fazli Ladan , Wang Yuzhuo , Collins Colin C. , Zoubeidi Amina , Gleave Martin
Published: April 2023

Supplemental Figure 4. Effects of AR-ASO on AR full length and AR-V7 levels in parental LNCaP and ENZ-R MR1F cells.
Supplementary Method Legends from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Table S1. Senescence pathway directed RT-PCR genomic expression analysis of UMSCC1 cells treated with 24 hour PF-05212384 (10 �M) or DMSO (10 �M) followed by irradiation (10 Gy) or mock irradiation.
Supplementary Figure S6 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Signaling consequences of afatinib monotherapy and comparison with lapatinib: Effects on downstream transducers.
Supplementary Figure S2 from Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
Authors: Leiker Andrew J. , DeGraff William , Choudhuri Rajani , Sowers Anastasia L. , Thetford Angela , Cook John A. , Van Waes Carter , Mitchell James B.
Published: April 2023

Supplementary Figure S2. Flow cytometry profiles of UMSCC1, UMSCC46, 1522, and plateau-phase UMSCC1 cells treated with PF-05212384 (10 Î¼M) for 24 hr with associated 24 hr DMSO (10 Î¼M) controls.
Supplementary Figure S4 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Effects on downstream transducers.
Supplementary Figure S1 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas
Authors: Leto Simonetta M. , Sassi Francesco , Catalano Irene , Torri Valter , Migliardi Giorgia , Zanella Eugenia R. , Throsby Mark , Bertotti Andrea , Trusolino Livio
Published: April 2023

Effects of anti-HER2 therapies in additional HER2-amplified patient-derived colorectal cancer tumorgrafts.
Supplementary Figure S7 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S7: Translational study endpoints (IHC) and subcutaneous in-vivo model. (A) Representative photos of primary tumor pEGFR and pAkt immunohistochemistry in each of the 6 subrenal model experiments. (B) Mean and sem of tumor volume of dual blockade (ERL+ BYL) versus single blockade (ERL, BYL) versus control (NT) over 28 days in the subcutaneous model (n=5 in each treatment group).
Supplementary Fig. 2 from Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Authors: Gebhardt Christoffer , Sevko Alexandra , Jiang Huanhuan , Lichtenberger Ramtin , Reith Maike , Tarnanidis Kathrin , Holland-Letz Tim , Umansky Ludmila , Beckhove Philipp , Sucker Antje , Schadendorf Dirk , Utikal Jochen , Umansky Viktor
Published: April 2023

Serum eotaxin-1 levels detected in patients before Ipi infusion (point 0), after the first (point 1) and second infusion (point 2)
Supplementary Figure S4 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S4: Western blotting dual blockade isobolograms: Isobolograms constructed for pERK, pAkt and pS6 inhibition by ERL* AEW (A) and ERL* BYL (B) for BxPC-3 and PANC-1. An IC50 additivity line was extrapolated based on the predicted single drug IC50 in three separate experiments. The combined IC50 values of dual inhibitors were plotted on the same graph. If the observed points lied below the additivity line, then the two drugs acted synergistically in inhibiting the respective signal.
Supplementary Figure S2 from Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma
Authors: Wong Matthew H. , Xue Aiqun , Julovi Sohel M. , Pavlakis Nick , Samra Jaswinder S. , Hugh Thomas J. , Gill Anthony J. , Peters Lyndsay , Baxter Robert C. , Smith Ross C.
Published: April 2023

Figure S2: Quantitation of immunofluorescence by confocal microscopy, average of 4 experiments: (A) E-cadherin and vimentin immunofluorescence. (B) Total ERK and Akt on immunofluorescence. (C, D) pAkt and pERK immunofluorescence. *P<0.05; **P<0.001; ***P<0.0001
Supplemental Materials and Methods from A Novel MAPK–microRNA Signature Is Predictive of Hormone-Therapy Resistance and Poor Outcome in ER-Positive Breast Cancer
Authors: Miller Philip C. , Clarke Jennifer , Koru-Sengul Tulay , Brinkman Joeli , El-Ashry Dorraya
Published: April 2023

Supplemental Materials and Methods. Additional description of common materials and methods not included in main body of manuscript
Supplementary Figure 2 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 2. Comparison of gene expression between PeCa and matched normal tissue for PRC2 complex members
Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Authors: Amaravadi Ravi K. , Hamilton Kathryn E. , Ma Xiaohong , Piao Shengfu , Portillo Armando Del , Nathanson Katherine L. , Carlino Matteo S. , Long Georgina V. , Puzanov Igor , Xu Xiaowei , Morrissette Jennifer J.D. , Tsai Kenneth Y. , Flaherty Keith T. , Sosman Jeffrey A. , Goodman Grant R. , McArthur Grant A. , Rustgi Anil K. , Metz David C. , Schuchter Lynn M. , Chapman Paul B. , Sepulveda Antonia R.
Published: April 2023

Supplemental Methods from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Supplementary Figure 1 from Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Authors: Feber Andrew , Arya Manit , de Winter Patricia , Saqib Muhammad , Nigam Raj , Malone Peter R. , Tan Wei Shen , Rodney Simon , Lechner Matthias , Freeman Alex , Jameson Charles , Muneer Asif , Beck Stephan , Kelly John D.
Published: April 2023

Supplementary Figure 1. Proportion of MVPs in penile cancers.
Supplemental Figure 1 from Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors
Authors: Amaravadi Ravi K. , Hamilton Kathryn E. , Ma Xiaohong , Piao Shengfu , Portillo Armando Del , Nathanson Katherine L. , Carlino Matteo S. , Long Georgina V. , Puzanov Igor , Xu Xiaowei , Morrissette Jennifer J.D. , Tsai Kenneth Y. , Flaherty Keith T. , Sosman Jeffrey A. , Goodman Grant R. , McArthur Grant A. , Rustgi Anil K. , Metz David C. , Schuchter Lynn M. , Chapman Paul B. , Sepulveda Antonia R.
Published: April 2023

Supplemental Figure 1. Endoscopic and histological H&E images of colonic polyps in a Magnification: 10X (bottom left); 200X (bottom right) BRAF mutant melanoma patient treated with long-term vemurafenib.
Supplementary Table S1 from Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Authors: Goldman Jonathan , Eckhardt S. Gail , Borad Mitesh J. , Curtis Kelly K. , Hidalgo Manuel , Calvo Emiliano , Ryan David P. , Wirth Lori J. , Parikh Asit , Partyka James , Faessel Helene , Gangolli Esha , Stewart Sally , Rosen Lee S. , Bowles Daniel W.
Published: April 2023

Supplementary Table S1. On-study patient deaths
Supplementary Table 6 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Fucosyltransferases (FUT) are no significant changes in the bladder cancer compared to the normal bladder tissues.
Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

Complete information of the detected peptides for the six bands of I and II by mass spectrometry.
Supplementary Figure 1, Tables S1-6 from Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
Authors: Masaki Ayako , Ishida Takashi , Maeda Yasuhiro , Suzuki Susumu , Ito Asahi , Takino Hisashi , Ogura Hiroka , Totani Haruhito , Yoshida Takashi , Kinoshita Shiori , Narita Tomoko , Ri Masaki , Kusumoto Shigeru , Inagaki Atsushi , Komatsu Hirokazu , Niimi Akio , Ueda Ryuzo , Utsunomiya Atae , Inagaki Hiroshi , Iida Shinsuke
Published: April 2023

Supplementary Figure 1, Tables S1-6. Supplementary Fig. S1. IDO expression scores in ATL cells Supplementary Table S1. Clinical characteristics of ATL patients Supplementary Table S2. Univariate Cox proportional hazard analysis for survival according to the serum level of Kyn, Trp, or Kyn/Trp ratio Supplementary Table S3. Multivariate analysis for OS in ATL patients Supplementary Table S4. Multivariate analysis for OS in ATL patients Supplementary Table S5. Multivariate analysis for OS in aggressive ATL patients Supplementary Table S6. Multivariate analysis for OS in aggressive ATL patients
Supplementary Figure 1 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo
Authors: Li Chong , Yang Zhao , Du Ying , Tang Haidong , Chen Jun , Hu Deqing , Fan Zusen
Published: April 2023

BCMab1 antibody suppressed cancerous growth in mice bearing primary human bladder cancer cells.
Supplementary Table S1 from Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Authors: Strekalova Elena , Malin Dmitry , Good David M. , Cryns Vincent L.
Published: April 2023

Supplementary Table S1. Composition of diets.
Supplementary Figure S2 from Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Authors: Strekalova Elena , Malin Dmitry , Good David M. , Cryns Vincent L.
Published: April 2023

Supplementary Figure S2. Methioninase sensitizes TNBC cells to lexatumumab.
SUPPLEMENTARY DATA from ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
Authors: Chu David , Paoletti Costanza , Gersch Christina , VanDenBerg Dustin A. , Zabransky Daniel J. , Cochran Rory L. , Wong Hong Yuen , Toro Patricia Valda , Cidado Justin , Croessmann Sarah , Erlanger Bracha , Cravero Karen , Kyker-Snowman Kelly , Button Berry , Parsons Heather A. , Dalton W. Brian , Gillani Riaz , Medford Arielle , Aung Kimberly , Tokudome Nahomi , Chinnaiyan Arul M. , Schott Anne , Robinson Dan , Jacks Karen S. , Lauring Josh , Hurley Paula J. , Hayes Daniel F. , Rae James M. , Park Ben Ho
Published: April 2023

Supplementary Methods Figure S1 ESR1 Y537SY537N and D538G probes are mutation specific. Figure S2 Patient 1 and Patient 14's plasma DNA. Table S1 Additional patient characteristics. Table S2 Primers used in this study.
Supplementary Tables 1-2, Supplementary Figure Legend from Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms
Authors: Khan Mohid S. , Kirkwood Amy A. , Tsigani Theodora , Lowe Helen , Goldstein Robert , Hartley John A. , Caplin Martyn E. , Meyer Tim
Published: April 2023

Table S1: Treatments undertaken with timing of imaging; S2: Changes in CgA at first post-treatment time-point (3-5 weeks) compared to baseline and effect on OS.
Supplementary Figures 1-2, Supplementary Tables 1-2 from p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
Authors: Hardwick Nicola R. , Frankel Paul , Ruel Christopher , Kilpatrick Julie , Tsai Weimin , Kos Ferdynand , Kaltcheva Teodora , Leong Lucille , Morgan Robert , Chung Vincent , Tinsley Raechelle , Eng Melissa , Wilczynski Sharon , Ellenhorn Joshua D.I. , Diamond Don J. , Cristea Mihaela
Published: April 2023

Figure S1: Frequency of Tregs does not significantly decline post treatment and does not correlate with p53-reactivity or PFS.; Figure S2: Frequency of MDSC does not significantly differ to healthy controls, does not decline post treatment and does not correlate with p53-reactivity or PFS.; Supplementary Table T1: Multi variation analysis* shows an association between progression free survival and frequency of p53-reactive T cells, disease stage and baseline MDSC. Supplementary Table T2: Correlations (Pearson) of variables included in multi variation analysis.
Supplemental Figure Legends from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure Legends. Figure Legends for supplemental figures
Supplemental Figure 5 from The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness
Authors: Thangavel Chellappagounder , Boopathi Ettickan , Ciment Steve , Liu Yi , O' Neill Raymond , Sharma Ankur , McMahon Steve B. , Mellert Hestia , Addya Sankar , Ertel Adam , Birbe Ruth , Fortina Paolo , Dicker Adam P. , Knudsen Karen E. , Den Robert B.
Published: April 2023

Supplemental Figure 5. RB status is retained in biopsy proven local recurrence.
Supplementary Table S1 from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Supplementary Table S1. Supplementary Table S1 describing clinicopathological characteristics of the analyzed cohorts in detail.
Supplementary Methods from Prognostic and Chemotherapy Predictive Value of Gene-Expression Phenotypes in Primary Lung Adenocarcinoma
Authors: Ringnér Markus , Jönsson Göran , Staaf Johan
Published: April 2023

Supplementary Methods. Document providing detailed information about cohorts and data analysis steps.
Figure S2 from Stem Cells Increase in Numbers in Perinecrotic Areas in Human Renal Cancer
Authors: Varna Mariana , Gapihan Guillaume , Feugeas Jean-Paul , Ratajczak Philippe , Tan Sophie , Ferreira Irmine , Leboeuf Christophe , Setterblad Niclas , Duval Arnaud , Verine Jérôme , Germain Stéphane , Mongiat-Artus Pierre , Janin Anne , Bousquet Guilhem
Published: April 2023

Figure S2. On xenograft RCC models non-responder to sunitinib, we assessed the distribution of CD133 positive cells
Supp. Table 2 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma
Authors: Calles Antonio , Sholl Lynette M. , Rodig Scott J. , Pelton Ashley K. , Hornick Jason L. , Butaney Mohit , Lydon Christine , Dahlberg Suzanne E. , Oxnard Geoffrey R. , Jackman David M. , Jänne Pasi A.
Published: April 2023

Supplementary Table S2. Panel of cancer cell lines with known LKB1 status tested for LKB1 IHC.
Supplementary Table 2 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Table 2. 10 OTUs with smallest P-values at genus and species levels. Comparisons are made between diarrhea and non-diarrhea patients
Supplementary Tables 1 - 2 from Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity
Authors: Mao Yumeng , Sarhan Dhifaf , Steven André , Seliger Barbara , Kiessling Rolf , Lundqvist Andreas
Published: April 2023

PDF file - 207K, Table S1. Cell line authentication. Table S2. Antibodies used for flow cytometry.
Supplementary Figure 3 from Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors
Authors: Pal Sumanta K. , Li Sierra M. , Wu Xiwei , Qin Hanjun , Kortylewski Marcin , Hsu JoAnn , Carmichael Courtney , Frankel Paul
Published: April 2023

Supplementary Figure 3. PC1 and PC2 from PCoA plotted against age, diarrhea status, first line therapy vs others and sunitinib vs other drugs
supplementary materials from Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer
Authors: Varkaris Andreas , Corn Paul G. , Parikh Nila U. , Efstathiou Eleni , Song Jian H. , Lee Yu-Chen , Aparicio Ana , Hoang Anh G. , Gaur Sanchaika , Thorpe Lynnelle , Maity Sankar N. , Bar Eli Menashe , Czerniak Bogdan A. , Shao Yiping , Alauddin Mian , Lin Sue-Hwa , Logothetis Christopher J. , Gallick Gary E.
Published: April 2023

supplementary materials and methods, supplementary tables and supplementary figure legends Supplemental Table 1: Patient Characteristics. Supplemental Table 2: Targeting sequences for c-met. Supplemental Table 3: Antibodies and Sources. Supplemental Table 4: Oligonucleotides for PCR Amplification of Mouse Alkaline Phosphatase and Osteonectin.
Supplementary Figure 1, Figure 2, Table 1, Table 2, Table 3, Table 4, Table 5, Table 6 from First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Authors: Meulendijks Didier , Jacob Wolfgang , Martinez-Garcia Maria , Taus Alvaro , Lolkema Martijn P. , Voest Emile E. , Langenberg Marlies H.G. , Fleitas Kanonnikoff Tania , Cervantes Andres , De Jonge Maja J. , Sleijfer Stefan , Soerensen Morten Mau , Thomas Marlene , Ceppi Maurizio , Meneses-Lorente Georgina , James Ian , Adessi Celine , Michielin Francesca , Abiraj Keelara , Bossenmaier Birgit , Schellens Jan H.M. , Weisser Martin , Lassen Ulrik N.
Published: April 2023

Figure 1 Mean ({plus minus}SD) serum lumretuzumab profiles following multiple ascending doses from 100 mg up to 2000 mg Figure 2 Percentage change in standardized uptake value maximum from baseline as assessed by FDG-PET at (a) Cycle 1 Day 14 and (b) Cycle 4 Day 14 Table 1 Summary of baseline and change in HER3 expression measured by IHC in skin and tumor biopsy samples pre and post treatment with lumretuzumab Table 2 Summary of change in expression of HER3, HER2, EGFR and cMET in fresh tumor biopsies compared to primary archival samples Table 3 Peripheral blood immunophenotyping (T, B and NK cells and NK subsets) from patients dosed with 2000 mg lumretuzumab Table 4 Ex-vivo activation potential of peripheral NK lymphocytes for all patients at ba seline and following exposure to lumretuzumab in the 2000 mg dose cohort Table 5 Summary of tumor immune effector cell infiltration Table 6 Tumor response to treatment (RECIST)
Figure S3 from Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
Authors: Curti Antonio , Ruggeri Loredana , Parisi Sarah , Bontadini Andrea , Dan Elisa , Motta Maria Rosa , Rizzi Simonetta , Trabanelli Sara , Ocadlikova Darina , Lecciso Mariangela , Giudice Valeria , Fruet Fiorenza , Urbani Elena , Papayannidis Cristina , Martinelli Giovanni , Bandini Giuseppe , Bonifazi Francesca , Lewis Russell E. , Cavo Michele , Velardi Andrea , Lemoli Roberto M.
Published: April 2023

Figure S3. Correlation between relapse rate and percentage of alloreactive clones at day 3 after infusion.
Supplementary Tables S4 from Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy
Authors: McBryan Jean , Fagan Ailís , McCartan Damian , Bane Fiona T. , Varešlija Damir , Cocchiglia Sinéad , Byrne Christopher , Bolger Jarlath , McIlroy Marie , Hudson Lance , Tibbitts Paul , Ó Gaora Peadar , Hill Arnold D. , Young Leonie S.
Published: April 2023

Supplementary Table S4: Patient information for patients A-L
Supplementary Figure Legends from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract
Authors: Sun Yun-Yan , Peng Shiwen , Han Liping , Qiu Jin , Song Liwen , Tsai Yachea , Yang Benjamin , Roden Richard B.S. , Trimble Cornelia L. , Hung Chien-Fu , Wu T.-C.
Published: April 2023

Supplementary Figure Legends
Supplemental Figure 4 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 4. Quantification of IHC data.
Supplemental Figure 3 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Authors: Nawrocki Steffan T. , Kelly Kevin R. , Smith Peter G. , Keaton Mignon , Carraway Hetty , Sekeres Mikkael A. , Maciejewski Jaroslaw P. , Carew Jennifer S.
Published: April 2023

Supplemental Figure 3. Schematic of pyrimidine nucleotide metabolism pathway.
Supplemental Table from Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells
Authors: Yoon Changhwan , Cho Soo-Jeong , Aksoy Bülent Arman , Park Do Joong , Schultz Nikolaus , Ryeom Sandra W. , Yoon Sam S.
Published: April 2023

Supplemental Table
Suppl Fig 5 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 5. MCL-1 knockdown displays limited effect on cytotoxicity and apoptosis in B-ALL model RS4;11.
Suppl Fig 4 from Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235
Authors: Hall Connor P. , Reynolds C. Patrick , Kang Min H.
Published: April 2023

Suppl Fig 4. Effect on PI3K pathway. (A) AKT1 knockdown effect on BEZ235, dexamethasone, and BEZ235 plus dexamethasone cytotoxicity.
Table S3 from Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Authors: Ben-Josef Edgar , George Asha , Regine William F. , Abrams Ross , Morgan Meredith , Thomas Dafydd , Schaefer Paul L. , DiPetrillo Thomas A. , Fromm Mitchel , Small William , Narayan Samir , Winter Kathryn , Griffith Kent A. , Guha Chandan , Williams Terence M.
Published: April 2023

Table S3. Multivariable Cox Proportional Hazards Models of Disease-free Survival Without CA19-9 (n=163)
Table S2 from Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas
Authors: Ben-Josef Edgar , George Asha , Regine William F. , Abrams Ross , Morgan Meredith , Thomas Dafydd , Schaefer Paul L. , DiPetrillo Thomas A. , Fromm Mitchel , Small William , Narayan Samir , Winter Kathryn , Griffith Kent A. , Guha Chandan , Williams Terence M.
Published: April 2023

Table S2. Multivariable Cox Proportional Hazards Models of Overall Survival Without CA19-9 (n=163)
Supplementary Figure 1 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Authors: Thomas Anish , Rajan Arun , Szabo Eva , Tomita Yusuke , Carter Corey A. , Scepura Barbara , Lopez-Chavez Ariel , Lee Min-Jung , Redon Christophe E. , Frosch Ari , Peer Cody J. , Chen Yuanbin , Piekarz Richard , Steinberg Seth M. , Trepel Jane B. , Figg William D. , Schrump David S. , Giaccone Giuseppe
Published: April 2023

Mean plasma concentration vs. time curve at belinostat 250 mg/m2.
Table S1 from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Table S1. Combination index (CI) values for OVCAR5 and SKOV3 cell lines treated with Cisplatin and Doxorubicin, Abraxane, Docetaxel or Paclitaxel.
Supplementary materials from Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Authors: Casagrande Naike , Celegato Marta , Borghese Cinzia , Mongiat Maurizio , Colombatti Alfonso , Aldinucci Donatella
Published: April 2023

Supplementary Materials and Methods, Legends to Figures S1, S2 and S3, References
Supplementary Figure S5qc from Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
Authors: Reinartz Roman , Wang Shanshan , Kebir Sied , Silver Daniel J. , Wieland Anja , Zheng Tong , Küpper Marius , Rauschenbach Laurèl , Fimmers Rolf , Shepherd Timothy M. , Trageser Daniel , Till Andreas , Schäfer Niklas , Glas Martin , Hillmer Axel M. , Cichon Sven , Smith Amy A. , Pietsch Torsten , Liu Ying , Reynolds Brent A. , Yachnis Anthony , Pincus David W. , Simon Matthias , Brüstle Oliver , Steindler Dennis A. , Scheffler Björn
Published: April 2023

Confirmatory subclone selection experiments applying clinical sample BN035.
Supplementary Figures 1-8 from Keap1–Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein
Authors: Chien Ming-Hsien , Lee Wei-Jiunn , Hsieh Feng-Koo , Li Chia-Feng , Cheng Tsu-Yao , Wang Ming-Yang , Chen Jin-Shing , Chow Jyh-Ming , Jan Yi-Hua , Hsiao Michael , Hua Kuo-Tai , Kuo Min-Liang
Published: April 2023

Supplementary Figures 1-8. Supplementary Figure 1: Stably expressing Keap1 by CL1-5 cells is accompanied by decreasing migratory and invasive abilities. Supplementary Figure 2: Manipulation of Keap1 expression (overexpression or knockdown) had no significant effect on the cell growth rate. Supplementary Figure 3: Keap1 suppresses the mobility of cancer cells. Supplementary Figure 4: Functional confirmation of Keap1 and Nrf2 expressions in CL1-0 and CL1-5 cells. Supplementary Figure 5: Cell proliferation was not affected by Nrf2 or S100P expression. Supplementary Figure 6: Representative IHC images of Nrf2 in lung cancer tissues from surgically resected specimens. Supplementary Figure 7: Keap1 regulates intra-pulmonary metastasis in a CL1-0 xenograft model. Supplementary Figure 8: Keap1 mediates the degradation of RhoA in CL1-5 cells.
Supplementary Table 3 from Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Authors: Dalin Martin G. , Desrichard Alexis , Katabi Nora , Makarov Vladimir , Walsh Logan A. , Lee Ken-Wing , Wang Qingguo , Armenia Joshua , West Lyndsay , Dogan Snjezana , Wang Lu , Ramaswami Deepa , Ho Alan L. , Ganly Ian , Solit David B. , Berger Michael F. , Schultz Nikolaus D. , Reis-Filho Jorge S. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S3. All mutations in cohort 1.
Supplementary Figure 1 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Authors: Magbanua Mark Jesus M. , Carey Lisa A. , DeLuca Amy , Hwang Jimmy , Scott Janet H. , Rimawi Mothaffar F. , Mayer Erica L. , Marcom P. Kelly , Liu Minetta C. , Esteva Francisco J. , Park John W. , Rugo Hope S.
Published: April 2023

Supplementary Figure 1. REMARK flow diagram of patients and sample collection and processing for each enumeration method (CellSearch and IE/FC). Blood samples from 102 patients with metastatic triple-negative breast cancer were collected at baseline and 7-14days after initiation of treatment. Circulating tumor cells in patients' blood from the same draw were contemporaneously enumerated by CellSearch and IE/FC.
Figure S2 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Qiu Fuman , Yang Lei , Ling Xiaoxuan , Yang Rongrong , Yang Xiaorong , Zhang Lisha , Fang Wenxiang , Xie Chenli , Huang Dongsheng , Zhou Yifeng , Lu Jiachun
Published: April 2023

Figure S2. The proliferation curves of A549 cells transfected with the miR-499-T vector, the miR-499-C vector and an "empty" vector without cisplatinum treatment during a week.
Figure S1 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Qiu Fuman , Yang Lei , Ling Xiaoxuan , Yang Rongrong , Yang Xiaorong , Zhang Lisha , Fang Wenxiang , Xie Chenli , Huang Dongsheng , Zhou Yifeng , Lu Jiachun
Published: April 2023

Figure S1. Genotyping of SNPs in the microRNAs by the TaqMan assay.
Supplementary Figure 4. RET and p70S6 kinase signaling in prostate cancer. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

A. Knockdown of RET with a second siRNA results in decreased p70S6 kinase phosphorylation in response to GFRα1. B and C. Knockdown of p70S6K with a second siRNA completely blocks increased proliferation (B) and invasion (C). The p values for significant differences by t-test are shown.
Supplemental Figures from Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Authors: Kim Hyoung , George Erin , Ragland Ryan L. , Rafail Stavros , Zhang Rugang , Krepler Clemens , Morgan Mark A. , Herlyn Meenhard , Brown Eric J. , Simpkins Fiona
Published: April 2023

Supplemental Figures with legends SUPPLEMENTAL FIGURE 1: PARPi treatment activates ATR/CHK1 and is synergistic with ATR and CHK1i in a BRCA1 mutant model SUPPLEMENTAL FIGURE 2: Colony Forming Assay Quantification. SUPPLEMENTAL FIGURE 3: Cell cycle analyses for PEO1 and PEO4 SUPPLEMENTAL FIGURE 4: ATR/CHK1 activation, cell cycle and apoptosis with increased PARPi concentration (5uM) in PEO4 (BRCA2REV) SUPPLEMENTAL FIGURE 5: pCHK1 expression in PDX treated tumors SUPPLEMENTAL FIGURE 6: Schema illustrating rational for synergy between PARP and ATR inhibition in high grade serous ovarian cancer.
Supplemental Table 3. from KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors
Authors: Wang Hao-Chen , Li Tzu-Ying , Chao Ying-Jui , Hou Ya-Chin , Hsueh Yuan-Shuo , Hsu Kai-Hsi , Shan Yan-Shen
Published: April 2023

List of primers used in real-time PCR experiments
Supplementary Tables from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

Supplementary Tables including Table 1, Table 2 and Table 3
Supplementary Tables from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Sup Table 1 : metabolic phenotyping; Sup Table 2 : List of primers
Figure S6 from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Activation of the Mitochondrial Pyruvate Carrier
Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

The cumulative incidence of non-relapse mortality are shown.
Supplementary Figure 5 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

Relapsed leukemia cells analysis by FACS.A, leukemia cells with bright CD19 expression obtained CR with MRD negative after CART19 therapy and relapsed with CD19 + leukemia cells (Patient 1). B, leukemia cells with dim CD19 expression obtained CR with MRD negative after CART19 therapy but relapsed with 2 subsets of CD19 + and - leukemia cells (Patient 2 and 3).
Supplementary Figure 2 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Authors: Hu Yongxian , Wu Zhao , Luo Yi , Shi Jimin , Yu Jian , Pu Chengfei , Liang Zuyu , Wei Guoqing , Cui Qu , Sun Jie , Jiang Jing , Xie Jue , Tan Yamin , Ni Wanmao , Tu Jifang , Wang Jinping , Jin Aiyun , Zhang Hao , Cai Zhen , Xiao Lei , Huang He
Published: April 2023

A, A representative diagram of the transduction efficiency evaluation of CART19s 5 days after lentivirus infection. B, Specific target cell lysis by CART19s. T cells or CART19s were co-cultured with K562-RFP cells or CD19-RFP-K562 cells at the indicated E:T ratio for overnight co-culture (24 hours). C, IFN-Î³ secretion measurements in supernatants in T cells or CART19 cells co-cultured with K562-RFP cells or CD19-RFP-K562 cells at the indicated E:T ratios for 24 hours.
Figure S3 from Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma
Authors: Iida Yuuki , Ciechanover Aaron , Marzese Diego M. , Hata Keisuke , Bustos Matias , Ono Shigeshi , Wang Jinhua , Salomon Matthew P. , Tran Kevin , Lam Stella , Hsu Sandy , Nelson Nellie , Kravtsova-Ivantsiv Yelena , Mills Gordon B. , Davies Michael A. , Hoon Dave S.B.
Published: April 2023

TIFF file for supplementary figure S3
Dataset S1 from Tumor Purity as an Underlying Key Factor in Glioma
Authors: Zhang Chuanbao , Cheng Wen , Ren Xiufang , Wang Zheng , Liu Xing , Li Guanzhang , Han Sheng , Jiang Tao , Wu Anhua
Published: April 2023

Dataset S1: Different frequency of CNAs in various purity conditions.
Supplemental Table from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Authors: Herman Sarah E.M. , Montraveta Arnau , Niemann Carsten U. , Mora-Jensen Helena , Gulrajani Michael , Krantz Fanny , Mantel Rose , Smith Lisa L. , McClanahan Fabienne , Harrington Bonnie K. , Colomer Dolors , Covey Todd , Byrd John C. , Izumi Raquel , Kaptein Allard , Ulrich Roger , Johnson Amy J. , Lannutti Brian J. , Wiestner Adrian , Woyach Jennifer A.
Published: April 2023

Supplementary Table S1. Kinase selectivity of acalabrutinib as assessed by DiscoveRX KinomeScan screening.
Supplemental Methods and Figure Legends from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Authors: Canella Alessandro , Welker Alessandra M. , Yoo Ji Young , Xu Jihong , Abas Fazly S. , Kesanakurti Divya , Nagarajan Prabakaran , Beattie Christine E. , Sulman Erik P. , Liu Joseph , Gumin Joy , Lang Frederick F. , Gurcan Metin N. , Kaur Balveen , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Supplemental Methods and Figure Legends
Figure S3 from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas
Authors: Canella Alessandro , Welker Alessandra M. , Yoo Ji Young , Xu Jihong , Abas Fazly S. , Kesanakurti Divya , Nagarajan Prabakaran , Beattie Christine E. , Sulman Erik P. , Liu Joseph , Gumin Joy , Lang Frederick F. , Gurcan Metin N. , Kaur Balveen , Sampath Deepa , Puduvalli Vinay K.
Published: April 2023

Figure S3
Supplementary Figure S2 from Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia
Authors: Jin Bei , Wang Chengyan , Li Juan , Du Xin , Ding Ke , Pan Jingxuan
Published: April 2023

Niclosamide promotes proteosome-dependent degradation of β-catenin and abrogates nuclear translocation of FOXM1 and β-catenin in CML cells.
Supplement figure legends from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Supplement figure legends for figure S1-S3
Figure S3 from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Figure S3 shows the expression levels of CTLA4 and IDO in GSE15932 microarray dataset
Figure S1 from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Figure S1 shows survival curve for PAAD with/out diabetes
Figures S1 - S20 from Mitochondrial BAX Determines the Predisposition to Apoptosis in Human AML
Authors: Reichenbach Frank , Wiedenmann Cornelius , Schalk Enrico , Becker Diana , Funk Kathrin , Scholz-Kreisel Peter , Todt Franziska , Wolleschak Denise , Döhner Konstanze , Marquardt Jens U. , Heidel Florian , Edlich Frank
Published: April 2023

S1 Western blot analysis of test cohort S2 relative mitochondrial protein localization of the tets cohort S3 KM-Kurves test cohort S4 ROC test cohort S5 comparison relative BAX/BAK localization S6 FLT3-ITD analysis test cohort S7 analysis based on protein level S8 SNV analysis S9 analysis of patient age S10 portion of patients with therapy-associated AML S11 Western blot analysis of BAX in 4 AML cell lines S12 Relative protein localization in 8 AML cell lines S13 PARP cleavage in HEL and OCI-3 S14 PARP cleavage in HEL, HL-60, EOL and THP-1 cells S15 analysis of FLT3-ITD in elderly patients S16 Western blot analysis of validation cohort S17 analysis of FLT3-ITD in patients from validation cohort S18 pretreatment blast count S19 therapeutic response S20 ROC validation cohort
Table S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Authors: Yi John S. , Ready Neal , Healy Patrick , Dumbauld Chelsae , Osborne Robyn , Berry Mark , Shoemaker Debra , Clarke Jeffrey , Crawford Jeffrey , Tong Betty , Harpole David , D'Amico Thomas A. , McSherry Frances , Dunphy Frank , McCall Shannon J. , Christensen Jared D. , Wang Xiaofei , Weinhold Kent J.
Published: April 2023

Demographics
Figure S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
Authors: Yi John S. , Ready Neal , Healy Patrick , Dumbauld Chelsae , Osborne Robyn , Berry Mark , Shoemaker Debra , Clarke Jeffrey , Crawford Jeffrey , Tong Betty , Harpole David , D'Amico Thomas A. , McSherry Frances , Dunphy Frank , McCall Shannon J. , Christensen Jared D. , Wang Xiaofei , Weinhold Kent J.
Published: April 2023

Spaghetti plots of CD4 and CD8 T cells by visits; stratified by overall response.
Supplementary table 1 from Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage–Induced Senescence Program in Gastric Cancer
Authors: Francica Paola , Nisa Lluís , Aebersold Daniel M. , Langer Rupert , Bladt Friedhelm , Blaukat Andree , Stroka Deborah , Martínez María Rodríguez , Zimmer Yitzhak , Medová Michaela
Published: April 2023

Table 1. Correlation between MET and FOXM1 expression levels with clinico-pathological features in a cohort of 72 patients with gastric cancer.
Supplemental Table S1 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Table S1: Genome-scale shRNA resistance screens identify ARID1A as common hit